Table 6.
Effect on BMD and fracture risk (fx) at different sites of available antiosteoporotic treatments: level of evidence.
| Drug | BMD | Vertebral fx | Non-vertebral fx | Hip fx |
|---|---|---|---|---|
| alendronate | 1 | 1 | 1 | 1 |
| clodronate 800mg/die/os | 1 | 1 | 1 | |
| etidronate | 1 | 1 | ||
| ibandronate | 1 | 1 | 1*** | |
| risedronate | 1 | 1 | 1 | 1 |
| zoledronate | 1 | 1 | 1 | 1 |
| teriparatide | 1 | 1 | 1 | |
| PTH1-84 | 1 | 1 | ||
| strontium ranelate | 1** | 1 | 1 | 1*** |
| ERT* | 1 | 1 | 1 | 1 |
| raloxifene | 1 | 1 | ||
| bazedoxifene | 1 | 1 | ||
| denosumab | 1 | 1 | 1 | 1 |
*
no longer recommended because of side effects;
**
also determined by strontium high-molecular weight per se;
***
as evidenced in post-hoc analyses.